Evidence map›Paper›PMID 32856142›Full record

ArticleAnnals of hematology2021

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.

Alessio Di Prima, Andrea Botticelli, Emilia Scalzulli, Gioia Colafigli, Sara Pepe, Chiara Lisi, Paolo Marchetti, Maurizio Martelli, Robin Foà, Massimo Breccia

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alessio Di PrimaHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Andrea BotticelliClinical and Molecular Department, Oncologia B Policlinico Umberto I, Sapienza University, Rome, Italy.
Emilia ScalzulliHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Gioia ColafigliHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Sara PepeHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Chiara LisiHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Paolo MarchettiClinical and Molecular Department, Oncologia B Policlinico Umberto I, Sapienza University, Rome, Italy.
Maurizio MartelliHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Robin FoàHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it.ORCID http://orcid.org/0000-0003-1163-6162
Policlinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCarcinoma, Squamous CellHumansMaleNitrilesPrimary MyelofibrosisProtein Kinase InhibitorsPyrazolesPyrimidinesSkin NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalcemiplimabNitrilesProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinib

Identifiers

PMID32856142
OpenAlexW3081857651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.